Get the Stockscreener App
59.62
0.93%
-0.5494
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $59.62, with a volume of 2.33M.
It is down -0.93% in the last 24 hours and up +3.71% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$60.17
Open:
$60
24h Volume:
2.33M
Relative Volume:
0.18
Market Cap:
$121.84B
Revenue:
$48.19B
Net Income/Loss:
$7.06B
P/E Ratio:
17.24
EPS:
3.4587
Net Cash Flow:
$12.85B
1W Performance:
+2.68%
1M Performance:
+3.71%
6M Performance:
+36.76%
1Y Performance:
+21.09%
1-Day Range:
$59.28
$60.12
1-Week Range:
$57.22
$60.48
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.67 | 122.85B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
926.33 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
232.90 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
206.03 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
202.37 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
118.37 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb Stock Forecast: What’s Driving Focus - Kalkine Media
Assetmark Inc. Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb to cut 206 more jobs in New Jersey (updated) - NJBIZ
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Why Bristol Myers Squibb (BMY) outpaced the stock market today - MSN
Bristol Myers Squibb Company $BMY Shares Sold by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount o... - ADVFN
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bain Capital’s Beeline Medicines Emerges With Assets From Bristol Myers Squibb - citybiz
New Bain biotech startup, building on BMS drugs, gets a name and a CEO - statnews.com
Raymond James reiterates Market Perform on Bristol-Myers stock - Investing.com
Raymond James reiterates Market Perform on Bristol-Myers stock By Investing.com - Investing.com Canada
Massachusetts Financial Services Co. MA Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Fidelity SAI U.S. Quality Index Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
F&V Capital Management, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
PIMCO Dividend and Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Company stock (US0897961004): Why does its oncology dominance matter more now f - AD HOC NEWS
Bristol Myers Squibb: Value Stock Analysis for Dividend Investors in 2026News and Statistics - IndexBox
Kirkland Advises Bristol-Myers Squibb on iPierian Buy - Law.com
Is Bristol-Myers Squibb Company (BMY) Among the 15 Cash-Rich Dividend Stocks to Invest in Right Now - Insider Monkey
American Express Company (AXP) – One of the 15 Cash-Rich Dividend Stocks to Invest in Right Now - Insider Monkey
Chemotherapy Market Set to Witness Massive Growth Through 2033 - openPR.com
Bristol Myers Squibb's Stock Position Boosted by Burney Co. - National Today
Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036 - GlobeNewswire Inc.
Bristol Myers Squibb Company $BMY Stock Position Lifted by Burney Co. - MarketBeat
Ritholtz Wealth Management Boosts Stake in Bristol Myers Squibb - National Today
Bristol Myers Squibb Downgraded to Buy Rating - National Today
Cantor Fitzgerald Reduces Stake in Bristol Myers Squibb - National Today
Wall Street Zen Downgrades Bristol Myers Squibb to Buy Rating - National Today
Bartlett & CO. Wealth Management LLC Has $7.26 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Assessing Bristol Myers Squibb (BMY) Valuation After Camzyos Data And T Cell Engager Collaboration News - Yahoo Finance
BMS and Oxford BioTherapeutics join forces in TCE discovery pact - Pharmaceutical Technology
Bristol Myers Squibb stock (US1101221083): Is its oncology pipeline strong enough to unlock new upsi - AD HOC NEWS
Bristol Myers Squibb Cancer Alliance Adds Weight To Valuation Debate - Yahoo Finance
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Bristol-Myers Squibb Company (BMY) stock price, news, quote and history - Yahoo Finance Singapore
Bristol-Myers Likely to Get Desired Court in Paxton Plavix Suit - Bloomberg Law News
Oxford BioTherapeutics Partners with Bristol Myers Squibb for Next-Gen T-Cell Therapies - National Today
Bristol-Myers Squibb Earnings Preview: What to Expect - Barchart.com
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours - Yahoo Finance UK
Bristol Myers Squibb Shares Sold by Franklin Street Advisors - National Today
Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst - Insider Monkey
MFS Blended Research Core Equity Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts - Yahoo Finance
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst - Benzinga
Cantor Fitzgerald raises Bristol-Myers Squibb stock price target to $54 - Investing.com Canada
Bristol-Myers Squibb: Vestmo Stock of the Week - Barron's
Guggenheim reiterates Bristol-Myers Squibb stock rating at Buy By Investing.com - Investing.com India
Guggenheim reiterates Bristol-Myers Squibb stock rating at Buy - Investing.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):